Overview

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Status:
Recruiting
Trial end date:
2032-10-01
Target enrollment:
Participant gender:
Summary
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Groupe Hospitalier Diaconesses Croix Saint-Simon
Collaborator:
GERCOR - Multidisciplinary Oncology Cooperative Group
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Epirubicin
Paclitaxel